Seeking Alpha

Seeking Alpha Portfolio App for iPad

992 people get ONCY articles and Market Currents by email alert.

Get email alerts on ONCY »

ONCY

Oncolytics Biotech, Inc.

5/21/2013, 5:13 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, March 28, 9:29 AM Oncolytics Biotech (ONCY) +8.7% premarket after announcing positive results from a midstage study of its lead product candidate Reolysin in treating squamous cell carcinoma of the lung. A sufficient number of responses in the first stage of the study were seen to proceed with enrollment in the second stage. Comment! [Healthcare, On the Move]
Thursday, March 28, 9:10 AM Premarket gainers: RPRX +75%. CTIC +14%. ONCY +8%. EXM +7%. DECK +6%. XONE +6%.
Losers: TWO -8%. FIVE -7%. GME -5%. 1 Comment [On the Move]
Monday, February 25, 12:36 PM Oncolytics Biotech (ONCY -1.5%) dips after closing out its previously announced underwritten public offering of 8M shares at $4. The company intends to use the net proceeds from the offering to fund its clinical trial and manufacturing program. 1 Comment [Healthcare, On the Move]
Wednesday, February 20, 12:45 PM Midday top 10 gainers: NVGN +46%. IMMY +33%. IKNX +29%. NTSP +29%. CRTX +22%. LZB +17%. CHLN +16%. RVLT +15%. CMGE +14%. TCX +14%.
Midday top 10 losers: HNR -39%. MM -36%. GMXR -19%. MEIL -19%. JAXB -18%. ANAD -16%. ODP -14%. ONCY -13%. BONE -13%. COBR -12%. Comment! [On the Move]
Wednesday, February 20, 10:22 AM Shares of Oncolytics Biotech (ONCY -13.8%) tank on resumption of trading after pricing its 8M share offering at $4, a 14% discount to Tuesday's close. The drug developer's shares were halted in premarket trading as the company disclosed the details. The company, which had had about 76.8M shares outstanding before today, unveiled the offering yesterday to raise funds for its clinical-trials and manufacturing programs. 1 Comment [Healthcare, On the Move]
Wednesday, February 20, 9:10 AM Premarket gainers: NTSP +30%. NVGN +14%. JASO +9%. SINA +8%. GDOT +8%. THLD +8%. RMBS +8%. OMX +7%. ODP +7%. MDRX +6%. GALE +5%.
Losers: HNR -41%. MM -27%. ONCY -12%. GRMN -9%. LIFE -5%. Comment! [On the Move]
Tuesday, February 19, 6:27 PM Oncolytics Biotech (ONCY) initiates a public stock offering for an undetermined amount of shares. The company says the size and price of the offering are to be determined at the time of pricing. It intends to use the net proceeds to fund its clinical trial program, manufacturing program and for general corporate and working capital purposes. Shares -7% AH. Comment! [Healthcare, On the Move]
Monday, February 11, 3:02 PM A genetically modified smallpox vaccine has been shown to shrink tumors in liver cancer patients and extends survival more than a year, a recent study found. The therapy, from closely held Jennerex, is called JX-594, or Pexa-Vec, and is currently being tested in people with advanced hepatocellular carcinoma. Treatment options for this advanced type of cancer are limited, and San Francisco-based Jennerex is competing with drug behemoths such as Amgen (AMGN -1.5%) and Merck (MRK +0.4%) in the space, as well as others such as Oncolytics Biotech (ONCY -5%) and Dendreon (DNDN -3.3%). 6 Comments
Friday, February 8, 1:00 PM Midday top 10 gainers: BDCO +32%. CZR +25%. ONCY +23%. LNKD +20%. SNCR +19%. GALT +13%. ZN +13%. FLT +12%. ZNGA +12%. ATVI +11%.
Midday top 10 losers: ETRM -55%. MSON -22%. GUID -21%. NUAN -19%. RVBD -18%. QKLS -16%. JE -14%. NSP -13%. STS -11%. SPWR -10%. Comment! [On the Move]
Friday, February 8, 9:07 AM Oncolytics Biotech (ONCY) +35.3% premarket after announcing positive results from a mid-stage clinical trial examining the use of its lead product candidate Reolysin in helping shrink tumors. ONCY says 95% of patients with squamous cell carcinoma of the lung using Reolysin intravenously in combination with carboplatin and paclitaxel exhibited overall tumor shrinkage. Comment! [Healthcare, On the Move]
Monday, January 28, 12:32 PM Oncolytics Biotech (ONCY -0.7%) announces preliminary results from a Phase I study examining the intravenous administration of Reolysin in combination with Folfiri in patients with metastatic colorectal cancer, saying the combination was safe and well tolerated and resulted in disease control in the majority of evaluable patients. Comment! [Healthcare]
Monday, December 17, 2012, 12:45 PM Midday top 10 gainers: GNVC +37%. CBOU +30%. HRT +16%. CEDC +15%. OCZ +13%. CPWR +13%. ONCY +13%. JVA +12%. VELT +12%. HTCH +12%.
Midday top 10 Losers: SCL -48%. GYRO -31%. END -20%. OPXA -13%. CLWR -12%. XUE -12%. SSE -11%. ALIM -11%. RVM -11%. NBG -9%. 1 Comment [On the Move]
Thursday, December 13, 2012, 12:45 PM Midday top 10 gainers: ONCY +51%. TELK +23%. PRGN +21%. GBR +17%. SDBT +16%. SAM +15%. BBY +15%. CLWR +14%. ZAGG +14%. TROV +13%.
Midday top 10 Losers: RIGL -35%. EVI -31%. HRG -26%. PTIE -19%. CBMX -18%. OSN -15%. MEIP -13%. DQ -12%. CSUN -12%. ALLT -11%. Comment! [On the Move]
Thursday, December 13, 2012, 9:10 AM Premarket gainers: TELK +28%. ONCY +22%. BBY +17%. CLWR +13%. CVS +5%. TSL +5%.
Losers: RIGL -33%. HRG -26%. Comment! [On the Move]
Thursday, December 13, 2012, 8:54 AM Oncolytics Biotech (ONCY) soars 20.3% after saying its Reolysin treatment, in combination with carboplatin and paclitaxel, performed well in a Phase III trial of patients with head and neck cancer. Of 105 patients, 86% exhibited tumour stabilization or shrinkage vs 67% in the control group. The combo including Reolysin was also better at shrinking tumors than the two other treatments on their own. (PR) Comment! [Healthcare, On the Move]
Monday, November 12, 2012, 3:45 PM Oncolytics Biotech (ONCY -2%) says it's appointed Kirk Look as it's new chief financial officer. Mr. Look has served as ONCY's controller since 2003. Comment! [Healthcare, On the Move]